Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C.

Author Information (click to view)

Manolakopoulos S, Zacharakis G, Zissis M, Giannakopoulos V,

Manolakopoulos S, Zacharakis G, Zissis M, Giannakopoulos V, (click to view)

Manolakopoulos S, Zacharakis G, Zissis M, Giannakopoulos V,

Share on FacebookTweet about this on TwitterShare on LinkedIn

Annals of gastroenterology : quarterly publication of the Hellenic Society of Gastroenterology 2016 05 1129(3) 282-96 doi 10.20524/aog.2016.0041


Daclatasvir (Daklinza™), a new oral direct-acting antiviral, is an inhibitor of hepatitis C virus NS5A protein and has recently been approved in the United States, Europe and Japan in chronic hepatitis C. It shows potent pangenotypic activity and moderately high genetic barrier to resistance improving the sustained virological response (SVR) rates. In COMMAND phase 2 trials, daclatasvir demonstrated high SVR rates in HCV genotype 1-4 chronically infected patients treated with peginterferon-a (pegIFNα) plus ribavirin (RBV). Furthermore, it produced even higher response rates in all-oral combination with sofosbuvir, an interferon-free regimen, with or without ribavirin, in patients with advanced liver disease, HCV/HIV coinfection, liver transplantation in ALLY studies and other real-world studies. This narrative review provides information on the pharmacological properties, role, efficacy and safety of daclatasvir-containing regimens in chronic hepatitis C patients. Daclatasvir administered once-daily in combination with sofosbuvir is an effective 12-week treatment in adult patients with chronic hepatitis C and is generally safe and well tolerated.

Submit a Comment

Your email address will not be published. Required fields are marked *

13 − five =